This suggests that HRD status may not be a useful predictor of the benefit of PARPi plus anti-PD-L1 therapy, at least in NSCLC, or that induction platinum exposure may have confounded this effect. The gene discussed is CD274; the disease is non-small cell lung carcinoma.